Evidence map›Paper›PMID 24885942›Full record

Trial reportBMC nephrology2014

Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.

Pablo Ureña-Torres, Dominique Prié, Karim Keddad, Peter Preston, Paul Wilde, Hong Wan, J Brian Copley

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01128179 (A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo-controlled Study to Assess the Effect of Lanthanum Carbonate on Intact FGF23 in Normo-phosphataemic Subjects With Stage 3 Chronic Kidney Disease), which is not on this map. Cited by 21 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 7 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01128179 phase2completednot on this map

A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo-controlled Study to Assess the Effect of Lanthanum Carbonate on Intact FGF23 in Normo-phosphataemic Subjects With Stage 3 Chronic Kidney Disease

TypeinterventionalSponsorShireRan2010 to 2012Enrolled35ConditionsChronic Kidney DiseaseArmsLanthanum carbonate, Placebo
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 7 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.Clinical journal of the American Society of Nephrology : CJASN · 2017
    Trial
  10. Article
  11. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021
    Article
  12. Review
  13. Article
  14. Review
  15. Dietary Phosphorus Intake and the Kidney.Annual review of nutrition · 2017
    Review
  16. Article
  17. Review
  18. Review
  19. Remediation of Rare Earth Element Pollutants by Sorption Process Using Organic Natural Sorbents.International journal of environmental research and public health · 2015
    Article
  20. Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Pablo Ureña-TorresService de Néphrologie-Dialyse, Clinique du Landy, Paris, France. urena.pablo@wanadoo.fr.
Dominique Prié
Karim Keddad
Peter Preston
Paul Wilde
Hong Wan
J Brian Copley
Takeda (United States) · USBasingstoke and North Hampshire Hospital · GBHôpital Necker-Enfants Malades · FRLaboratoire Vision Action Cognition · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh levels of circulating fibroblast growth factor 23 (FGF23) are associated with chronic kidney disease (CKD) progression and high mortality. In the Phosphate Reduction Evaluation of FGF23 in Early CKD Treatment (PREFECT) study, we assessed the effect of reducing intestinal phosphate absorption using lanthanum carbonate on FGF23 levels in normophosphatemic patients with CKD stage 3.

methodsThirty-five individuals were randomized to lanthanum carbonate 3000 mg/day (n=23) or placebo (n=12) for 12 weeks. Levels of intact FGF23 (iFGF23), C-terminal FGF23, serum and urinary phosphate and calcium, intact parathyroid hormone and 1,25-dihydroxyvitamin D were assessed.

resultsThe median age was 65 years in the lanthanum group and 73 years in the placebo group; 58.8% and 41.7% were men, respectively. No significant difference was seen in mean iFGF23 between groups at week 12. There was, however, a transient reduction from baseline in iFGF23 in the lanthanum group at week 1, from 70.5 pg/ml to 51.9 pg/ml, which was not seen in the placebo group; this between-group difference in percentage change from baseline was significant in post hoc analyses (p=0.0102). Urinary phosphate decreased after 1 week of lanthanum treatment and remained low at week 12.

conclusionsReducing intestinal phosphate absorption with lanthanum carbonate did not lead to sustained reductions in iFGF23 in patients with CKD stage 3, although phosphaturia decreased. This suggests that factors other than phosphate burden may be responsible for driving increases in circulating FGF23 in patients with CKD.

trial registrationClinicalTrials.gov NCT01128179, 20 May 2010.

Indexed as

AdultAgedAged, 80 and overBiomarkersDouble-Blind MethodFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansLanthanumMaleMiddle AgedPhosphorusPlacebo EffectReference ValuesRenal Insufficiency, ChronicBiomarkersFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsLanthanumlanthanum carbonatePhosphorus

Identifiers

PMID24885942
PMCPMC4107721
OpenAlexW2071966346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.